Innovation and Product Empowerment: Innovative Pharma & MedTech Selection Conference Successfully Held in Beijing!
On the morning of May 10, 2024, the 8th Future Medical Ecosystem Expo Innovative Drugs and Medical Devices Selection Conference, hosted by VB100, VCBeat, Eggshell Research Institute, and Arterial Orange, and organized by Saibailan Company, was grandly held at the Yichuang International Convention and Exhibition Center in Yizhuang, Beijing. The conference gathered outstanding innovative pharmaceutical and medical device enterprises from across China, showcasing the latest medical devices, innovative drugs, and rehabilitation and wellness products.
The conference was moderated by Xiang Junjie of Saibailan. In his opening remarks, he stated, “In this era of rapid advancement in medical technology, every innovation has the potential to transform our understanding and management of health.” He emphasized the significance of the conference and welcomed all distinguished guests and colleagues.
Sai Bailan, Xiang Junjie
The conference was divided into two main segments: promotion of innovative pharmaceutical and medical device products, and promotion of innovative health and rehabilitation products. During the session on innovative pharmaceutical and medical device products, 12 companies showcased their latest achievements in the field of medical devices. These products not only meet specialized clinical needs but also feature breakthrough innovations in technology and efficiency.
The conference also invited representatives from renowned domestic and international pharmaceutical and medical device distributors, as well as private healthcare institutions. Their participation provided a broader platform for the market promotion and application of these innovative products. The online live-streaming platform also offered interested viewers the opportunity to submit expressions of interest for collaboration.
During the product showcase, Huang Baofu from Nanjing Jingjie Biotechnology Co., Ltd. introduced Jingjie Technology as a high-tech enterprise focused on the research, development, and application of microfluidic electrochemical sensing technology, dedicated to the production and sales of innovative POCT products. The company boasts strong R&D capabilities and extensive technical expertise. Its product portfolio includes China’s first fully dry electrolyte analyzer, the only lactate testing product in China with clinical device registration certification, and multifunctional handheld testers. The company’s products have obtained medical device registration certificates. With a nearly 10,000-square-meter R&D and production base in Nanjing Biovalley, the company holds independent intellectual property rights for over 200 core raw materials. Its market presence not only covers domestic sales but also extends to international markets, including the United States, Belgium, and Switzerland.
Nanjing Jingjie Biotechnology Co., Ltd. Huang Baofu
Chen Yujie from Shanghai Yisi Medical Technology Co., Ltd. shared that his company is an enterprise dedicated to the field of minimally invasive surgery. Leveraging its standardized quality management system and regulatory affairs department, it has successfully launched four major product lines: endoscopic staplers, energy device platforms, surgical support products, and optical imaging products. The company’s products are widely used in more than 80 countries and regions worldwide, with significant breakthroughs achieved particularly in the U.S. and EU markets. Prioritizing patent protection, the company holds 270 patents and over 155 global certifications. Its innovative product, the easyEndo Flex powered stapler, greatly enhances clinical safety and convenience through advantages such as a 60-degree large articulation angle, detachable jaw design, anvil fixation design, and ergonomic design.
Shanghai Yisi Medical Technology Co., Ltd. Chen Yujie
Liu Huan from Boyin Hearing (Shanghai) Co., Ltd. introduced the company’s focus on hearing aids and other products related to hearing health. He emphasized that Boyin Hearing has established production bases in Shanghai, Shenzhen, Suzhou, and Changsha, set up an R&D center in Chengdu, and launched its “Hearing Earth” franchise and investment promotion project in Beijing. The company’s product portfolio includes the Tangchao series of hearing aids, which have gained market recognition for their high cost-performance ratio, as well as the upcoming Shuting product line, specifically designed to meet the needs of individuals with severe hearing loss. Additionally, the company has launched behind-the-ear (BTE) hearing aids and innovative bone-conduction hearing aids. The latter transmits sound through the skull, features advanced chips and algorithms for noise reduction, and supports self-administered audiometry and Bluetooth connectivity via a mobile app.
Boyin Hearing (Shanghai) Co., Ltd. Liu Huan
Cao Bo, Founder and CEO of Rongchong Biomedical (Shenzhen) Co., Ltd., introduced that the company specializes in interventional therapies for cardiovascular and cerebrovascular diseases. Its flagship product is the Sirocone drug-coated balloon, which aims to achieve “implant-free intervention” and is dedicated to reducing treatment risks for patients with cardiovascular and cerebrovascular conditions. The Sirocone balloon features several core advantages: it utilizes a safe and effective rapamycin drug coating, provides sustained drug release for up to 90 days, employs polymer-free technology to reduce the risks of inflammation and thrombosis, and holds an invention patent. Clinical data demonstrate its superior efficacy and safety profile, with no adverse events reported. The product line offers comprehensive specifications and broad indications. Currently, the coronary products are nearing registration approval and have completed clinical validation at multiple Grade A tertiary hospitals.
Rongchong Biomedical Technology (Shenzhen) Co., Ltd. Cao Bo
Yang Pei, Marketing Manager of Beijing New羿 Biotechnology Co., Ltd., introduced at the event that New羿 Biotech is a high-tech enterprise focused on the research and development of digital PCR systems and related products. Leveraging its full-chain core technologies, the company has maintained a leading market share for three consecutive years. The digital PCR technology launched by the company is an upgraded version of quantitative fluorescent PCR (qPCR), offering higher sensitivity and quantification accuracy, and is recognized as the gold standard for nucleic acid quantification. New羿 Biotech’s product portfolio includes multiple digital PCR systems such as TD-1, TD-2, and TD-3, tailored to diverse market demands. These systems feature multi-channel detection capabilities, ease of operation, high throughput, and rapid processing, and have obtained FDA, CE, and domestic certifications. The company’s products demonstrate significant advantages in fields such as tumor liquid biopsy, small-sample testing, and sepsis diagnosis. Its upcoming new products also show great potential in detecting prevalent diseases such as thyroid cancer. Furthermore, New羿 Biotech has established a product layout in areas including POCT and qPCR, providing comprehensive solutions. The company holds more than 200 patent applications and over 40 granted patents, and has published more than 40 academic papers.
Beijing New E Biotechnology Co., Ltd. Yang Pei
During the event, Wu Xingyu, Head of R&D at Shenzhen Better Micro Medical Technology Co., Ltd., provided a detailed introduction to the company. Better Micro is a Shenzhen-based enterprise focused on medical innovation. Since its establishment in 2021, the company has rapidly assembled an R&D team and constructed GMP-compliant manufacturing facilities. In its second year, it successfully developed three products and obtained both production and operation licenses. The company’s product portfolio covers three major categories: recanalization devices, embolization devices, and functional catheters, aiming to provide therapeutic solutions for vascular diseases such as thrombosis, calcification, and aneurysms. Representative products include steerable sheaths with 180-degree tip deflection, endovascular retrieval devices, microcatheters in various specifications, detachable and controllable coils, transjugular intrahepatic puncture systems, compliant balloons, peripheral deep vein thrombectomy systems, pulmonary embolism removal systems, portable thrombus aspiration devices, and peripheral vascular plaque and foreign body removal devices. These products have demonstrated favorable safety and efficacy in clinical trials, with some matching or even surpassing the performance of international competitors. Committed to continuous technological innovation, Better Micro strives to deliver more high-quality products and services to the healthcare sector.
Shenzhen Better Micro Medical Technology Co., Ltd. Wu Xingyu
Qi Huafeng, Marketing Director of Ansukang Medical (Suzhou) Co., Ltd., introduced the company’s commitment to developing innovative medical devices. Its flagship product is the world’s first host-free ultrasonic scalpel, designed to lead the future development of ultrasonic surgical technology. Through miniaturization and intelligent design, this product simplifies the complex components of traditional ultrasonic scalpels, consisting only of an integrated handpiece, a disposable surgical tip, and a portable unit. This significantly improves space utilization in operating rooms and enhances operational convenience. The host-free design reduces hospitals’ procurement and maintenance costs while minimizing medical waste generation. The device also features an integrated screen displaying usage counts and allowing power level adjustments, thereby improving surgical safety and efficiency. Furthermore, eliminating concerns about host compatibility facilitates promotion and management by distributors. The product has received positive feedback from hospitals, demonstrating its market potential. Guided by a focus on clinical needs and pain points, Ansukang Medical continues to innovate, striving to provide high-value solutions for the healthcare sector.
Ansukang Medical (Suzhou) Co., Ltd. Qi Huafeng
Ningbo Jiajia Jianjian Biotechnology Co., Ltd. has launched a convenient home health testing device. Ms. Li Miao, General Manager, stated that Jiajia Jianjian enables users to perform various health tests at home using different test strips, including screening for myocardial infarction, kidney injury, and eugenics-related indicators, thereby assisting in early disease prevention and health management. The company’s founder, Dr. Deng Shuangsheng, brings nearly 30 years of experience in rapid diagnostic research, and the majority of the team hails from leading medical device companies. The product has obtained domestic certification and is currently expanding into overseas markets.
Ningbo Jiajia Jianjian Biotechnology Co., Ltd. Li Miao
Sun Jingqi, General Manager of Shanghai Ruishi Health Technology Co., Ltd., emphasized in his presentation that it is crucial to keep children’s myopia below 500 degrees before the age of 18; exceeding this threshold necessitates annual fundus examinations. Founded in late 2019, Ruishi Technology specializes in myopia management and prevention, and has promoted its services through science popularization and product sales across nearly 3,000 stores nationwide.
Shanghai Ruishi Health Technology Co., Ltd. Sun Jingqi
Chen Shanshan, General Manager of Suzhou Kehong Health Industry Insurance Company, stated at a recent health forum that the company is committed to addressing 70% of sleep-related health issues. By leveraging innovative services such as mini-program-based screening, personalized diagnosis and treatment, corporate partnerships, and offline experience centers, the company provides comprehensive sleep health solutions aimed at improving the sleep quality of the general population and plans to expand its service network across China.
Suzhou Kehong Health Industry Insurance Company Chen Shanshan
Song Haoran, R&D Director at Yishu Medical, provided a detailed introduction to the company’s latest innovative product, designed to address xerostomia (dry mouth) in clinical care. Song pointed out that China’s nursing market is growing by over RMB 2 trillion annually, with the contradiction between shortages in nursing resources and diverse patient needs becoming increasingly prominent. By studying salivary gland flow rates, Yishu Medical has developed an easy-to-use nursing product that has obtained Class II medical device certification and successfully served more than 5,000 patients. The product features a simple design requiring only a single step to provide continuous relief from dry mouth symptoms within 24 hours. Looking ahead, Yishu Medical plans to launch an AI-powered dry mouth care system offering customized solutions, and aims to build a comprehensive, scenario-based intelligent oral care system to improve patients’ overall oral health.
Yishu Medical Song Haoran
Li Chao, head of the Silver Hair Sector at Saibailan, provided a detailed introduction to the vision and development direction of the Silver Hair Sector platform to the audience and partners during the conference. Li pointed out that with the accelerating aging process in China, the population aged 60 and above has exceeded 290 million, accounting for more than 20% of the national total, which brings tremendous opportunities to the silver economy.
The Silver Economy Platform is dedicated to focusing on the development of the silver economy industry, bringing together professionals from government bodies, industry organizations, and academia, as well as high-quality enterprises and partners, to jointly create a comprehensive platform for the silver economy. The platform includes databases for projects, talent, best practices, experts, and suppliers, aiming to provide resources and support for businesses and service providers within the industry.
Li Chao stated that in 2024, the Silver Economy sector will build a comprehensive collaboration matrix, inviting more high-quality suppliers and industry talent to join, covering areas such as age-friendly renovations, smart health and elderly care devices, medical-assistance and elderly care services, and health management. Cablan will open up its agent and distributor resources accumulated over more than a decade, providing partners with precise market matching and promotional services through the Baitong Investment Promotion Assistant platform and its media matrix.
Furthermore, the silver economy sector has developed SaaS platforms tailored for medical accompaniment and home care services, providing comprehensive digital solutions for users, service providers, and operators. Li Chao called on enterprises with relevant products and services to integrate their technologies and jointly promote the development of the silver economy.
Li Chao concluded by emphasizing that, as a leading media outlet in the pharmaceutical and healthcare industry, Saibailan will continue to leverage its influence and resource advantages to provide strong support and impetus for the development of the silver economy. Through a series of online and offline activities, industry forums, and exhibitions, Saibailan Silver Economy Sector will facilitate communication and collaboration among all parties, jointly exploring and addressing the challenges and opportunities in the development of the silver economy.
CyberBlue Li Chao
At this event, numerous enterprises and institutions showcased their innovative achievements and technological breakthroughs in the fields of medical devices and health management. Through such exhibitions and exchanges, industry collaboration and communication were further strengthened, driving technological advancements and market applications in the medical device and health management sectors.
In the future, with continuous technological advancements and growing market demand, the fields of medical devices and health management will witness greater innovation and development opportunities. Through ongoing technological innovation and market promotion, these advanced medical devices and health management products will bring significant benefits to more patients and consumers, enhancing their quality of life and health outcomes.
Overall, this event not only showcased the latest technologies and products in the fields of medical devices and health management but also provided a platform for exchange and collaboration among enterprises and institutions within the industry. Through such initiatives, further progress and development in the sector have been promoted, laying a solid foundation for future innovation and market applications.